Your browser doesn't support javascript.
loading
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Thielmann, Carl M; Matull, Johanna; Zaremba, Anne; Murali, Rajmohan; Chorti, Eleftheria; Lodde, Georg; Jansen, Philipp; Herbst, Rudolf; Terheyden, Patrick; Utikal, Jochen; Pföhler, Claudia; Ulrich, Jens; Kreuter, Alexander; Mohr, Peter; Gutzmer, Ralf; Meier, Friedegund; Dippel, Edgar; Weichenthal, Michael; Kretz, Julia; Möller, Inga; Sucker, Antje; Paschen, Annette; Livingstone, Elisabeth; Zimmer, Lisa; Hadaschik, Eva; Ugurel, Selma; Schadendorf, Dirk; Griewank, Klaus G.
Affiliation
  • Thielmann CM; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany. Electronic address: carlmaximilian.thielmann@uk-essen.de.
  • Matull J; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Zaremba A; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Murali R; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Chorti E; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Lodde G; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Jansen P; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Herbst R; Skin Cancer Unit, Helios Klinikum Erfurt, Erfurt, Germany.
  • Terheyden P; Department of Dermatology, UKSH Campus Lübeck, Lübeck, Germany.
  • Utikal J; Skin Cancer Unit, German Cancer Research Center (DKFZ), Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Heidelberg, Germany.
  • Pföhler C; Department of Dermatology, Saarland University Medical School, Homburg, Saar, Germany.
  • Ulrich J; Department of Dermatology and Venereology, Harzklinikum Dorothea Christiane Erxleben, Quedlinburg, Germany.
  • Kreuter A; Department of Dermatology, Venereology and Allergology, HELIOS St. Elisabeth Klinik Oberhausen, University Witten/Herdecke, Oberhausen, Germany.
  • Mohr P; Dermatological Center Buxtehude, Elbe Kliniken Buxtehude, Buxtehude, Germany.
  • Gutzmer R; Skin Cancer Center, Hannover Medical School, Hannover, Germany; Department of Dermatology, Mühlenkreiskliniken Minden, Minden, Germany.
  • Meier F; Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
  • Dippel E; Department of Dermatology Ludwigshafen, Klinikum der Stadt Ludwigshafen Am Rhein GGmbH, Ludwigshafen, Germany.
  • Weichenthal M; Department of Dermatology, University Hospital Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.
  • Kretz J; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Möller I; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Sucker A; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Paschen A; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Livingstone E; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Zimmer L; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Hadaschik E; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Ugurel S; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Schadendorf D; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany.
  • Griewank KG; Department of Dermatology, University Hospital Essen, University of Duisburg, German Cancer Consortium (DKTK), Partner Site, Essen, Germany. Electronic address: klaus.griewank@uk-essen.de.
Eur J Cancer ; 161: 99-107, 2022 01.
Article in En | MEDLINE | ID: mdl-34936949
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Promoter Regions, Genetic / Telomerase / Mitogen-Activated Protein Kinase Kinases / Proto-Oncogene Proteins B-raf / Melanoma / Mutation Type of study: Observational_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 2022 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Promoter Regions, Genetic / Telomerase / Mitogen-Activated Protein Kinase Kinases / Proto-Oncogene Proteins B-raf / Melanoma / Mutation Type of study: Observational_studies / Risk_factors_studies Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Eur J Cancer Year: 2022 Document type: Article Country of publication: United kingdom